SF Stifel Financial Corp.

Stifel Adds Two Biopharma Investment Bankers, Enhancing Premier Healthcare Franchise

Stifel Adds Two Biopharma Investment Bankers, Enhancing Premier Healthcare Franchise

ST. LOUIS, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced two senior hires in its Investment Banking Group. Sean Cessna joins as Managing Director and Titus Phoro joins as Director. Both are based in San Francisco and will lead Stifel’s West Coast efforts in the burgeoning biopharma space.

“The addition of experienced bankers like Sean and Titus is part of our ongoing commitment to building a leading healthcare investment banking franchise,” said Mark Dempster, Co-Head of Healthcare Investment Banking at Stifel. “Biopharma has been, and continues to be, one of our strongest sectors and is an area where we believe there is still tremendous opportunity to continue growing our business,” added Declan Quirke, Co-Head of Healthcare Investment Banking at Stifel. “We are very pleased to have Sean and Titus join the team.”

Sean Cessna has more than 20 years of experience in investment banking with a primary focus on biopharmaceutical companies. Prior to joining Stifel, Mr. Cessna was Head of Healthcare Investment Banking at JMP Securities LLC overseeing the biopharmaceutical, medical device, healthcare services, and healthcare IT practices. Before joining JMP in 2011, he was a senior calling officer focused on life sciences companies in the healthcare investment banking team at Piper Jaffray and a member of the healthcare investment banking team at RBC Capital Markets. Earlier, Mr. Cessna worked in the investment banking group at Lehman Brothers and the mergers & acquisitions group at the Geneva Corporate Finance division of Citigroup. Mr. Cessna received an MBA from the University of Michigan and a B.S. in finance from the University of Oregon.

Titus Phoro also joins Stifel from JMP, where he was a Director in the firm’s healthcare investment banking group working with both public and private biopharma companies. A registered pharmacist, Dr. Phoro has also held positions in the healthcare investment banking groups at RBC Capital Markets and Jefferies & Company. He holds an MBA from the University of Chicago Booth School of Business and a Doctor of Pharmacy degree from Texas Southern University.

“Helping emerging growth companies realize their goals is in Stifel’s DNA,” said Mr. Cessna. “Stifel provides a best-in-class platform for us to serve clients with broad advisory and capital-raising capabilities, and we’re happy to join the team.”

Earlier this year, Stifel hired Senior Analysts Paul Matteis from Leerink and Derek Archila from Oppenheimer to augment the firm’s equity research coverage of the biotechnology sector. Melissa Scott also joined the firm from Morgan Stanley as a dedicated equity sales specialist focused on biotechnology companies.

Since 2010, Stifel’s Healthcare Investment Banking Group has executed more than 300 capital markets transactions, raising more than $32 billion for our clients. In that same timeframe, the group has also advised on 66 merger, acquisition, collaboration and strategic transactions representing approximately $13 billion in aggregate disclosed deal value. 

Stifel Company Information

Stifel Financial Corp. (NYSE: SF) is a financial services holding company headquartered in St. Louis, Missouri, that conducts its banking, securities, and financial services business through several wholly owned subsidiaries.  Stifel’s broker-dealer clients are served in the United States through Stifel, Nicolaus & Company, Incorporated, including its Eaton Partners business division; Keefe, Bruyette & Woods, Inc.; Miller Buckfire & Co., LLC; Century Securities Associates, Inc., and in the United Kingdom and Europe through Stifel Nicolaus Europe Limited.  The Company’s broker-dealer affiliates provide securities brokerage, investment banking, trading, investment advisory, and related financial services to individual investors, professional money managers, businesses, and municipalities.  Stifel Bank and Stifel Bank & Trust offer a full range of consumer and commercial lending solutions.  Stifel Trust Company, N.A. and Stifel Trust Company Delaware, N.A. offer trust and related services.  To learn more about Stifel, please visit the Company’s website at

Media Contact

Neil Shapiro, (212) 271-3447

Investor Relations Contact

Joel Jeffrey, (212) 271-3610

 

EN
04/12/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Stifel Financial Corp.

 PRESS RELEASE

Stifel Welcomes Veteran Healthcare Bankers Ajay Pathak and Bill Reisne...

Stifel Welcomes Veteran Healthcare Bankers Ajay Pathak and Bill Reisner as Managing Directors in Public Finance New Hires Underscore Stifel’s Accelerated Investment in Public Finance Healthcare Platform  ST. LOUIS, March 12, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced that Ajay Pathak and Bill Reisner have joined the firm as Managing Directors in Stifel’s Public Finance group to co-lead a differentiated healthcare practice. Both will be based in St. Louis, where they will accelerate the continued expansion of Stifel’s public finance platform with a unique ...

 PRESS RELEASE

Stifel Reports January 2026 Operating Data

Stifel Reports January 2026 Operating Data ST. LOUIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today reported selected operating results for January 31, 2026, to provide timely information to investors on certain key performance metrics. Due to the limited nature of this data, a consistent correlation to earnings should not be assumed. Ronald J. Kruszewski, Chairman and Chief Executive Officer, said, “In January, total client assets and fee-based client assets reached record levels, increasing 10% and 16% year over year, respectively, driven by market appreciat...

 PRESS RELEASE

Stifel Reports Record Full Year Results, Announces 11% Common Stock Di...

Stifel Reports Record Full Year Results, Announces 11% Common Stock Dividend Increase and Three-For-Two Stock Split ST. LOUIS, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today reported net revenues of $1.56 billion for the three months ended December 31, 2025, compared with $1.36 billion a year ago. Net income available to common shareholders was $255.0 million, or $2.31 per diluted common share, compared with $234.7 million, or $2.09 per diluted common share for the fourth quarter of 2024. Non-GAAP net income available to common shareholders was $290.0 million, o...

 PRESS RELEASE

Stifel Announces a Three-for-Two Stock Split, 11% Increase to Its Comm...

Stifel Announces a Three-for-Two Stock Split, 11% Increase to Its Common Stock Dividend & Declares Preferred Stock Cash Dividend Represents Ninth Consecutive Annual Dividend Increase Delivered to Shareholders ST. LOUIS, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced that its Board of Directors declared a three-for-two stock split of Stifel’s common stock in the form of a 50% stock dividend to be distributed on February 26, 2026, to shareholders of record at the close of business on February 12, 2026. Shareholders will receive one additional share of ...

 PRESS RELEASE

Stifel Financial Schedules Fourth Quarter and Full Year 2025 Financial...

Stifel Financial Schedules Fourth Quarter and Full Year 2025 Financial Results Conference Call ST. LOUIS, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) will release its fourth quarter & full year 2025 financial results before the market opens on Wednesday, January 28, 2026. The company will host a conference call to review the results at 9:30 a.m. Eastern time that same day. The conference call may include forward-looking statements. All interested parties are invited to listen to Stifel Chairman and CEO Ronald J. Kruszewski by dialing (800) 330-6710 and referencing...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch